Biotech | August 28, 2022
Moderna files for emergency use of BA.4/BA.5 Omicron booster
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Collaboration supports multiple discovery efforts, including vaccines
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Subscribe To Our Newsletter & Stay Updated
